The preferred timing of treatment of nonculprit lesions in patients with ST-segment elevation myocardial infarction (STEMI) ...

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

A new FDA program is being promoted as a tool to facilitate the development and approval of therapies that are important for society. But it risks undermining regulatory innovation and trust in ...

Recognizing that half of eligible children are not enrolled in the supplementary nutrition program for women, infants, and ...

Explore this issue of The New England Journal of Medicine (Vol. 0 No. 0).

CME activities, cases, challenges, videos, and more teaching and learning tools from the New England Journal of Medicine.

An 82-year-old woman with a history of congestive heart failure was admitted to this hospital for volume overload. Ascites, ...

Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based ...

Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...